Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Seems as though investors are still rewarding sheer weight loss over tolerability in the obesity drug race.
The FDA moved at a rapid clip with a new myeloma approval under its priority voucher pilot. Meanwhile, Moderna is trying to reset its future around oncology.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
